ClinicalTrials.gg
CompletedNCT04604899Updated Jul 16, 2024Results posted

Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa

A Phase 2 interventional study of human retinal progenitor cells in Retinitis Pigmentosa, sponsored by jCyte, Inc. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-16.

Sponsored by jCyte, Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 119 studies in Retinitis Pigmentosa with a site in United States — 20 open to participants now, 44 under way, 6 of them phase 3. Retinitis Pigmentosa · United States.

Enrollment
26th of 78
30 · median 21
Started
2020
with 8 others
Phase 2
15 of 119
none open now
Registered
82nd of 119
by date
Lead sponsor
4 of 119
jCyte, Inc

Among the 119 studies in Retinitis Pigmentosa with a site in United States, this one is the 26th largest by enrollment of the 78 interventional ones that give a count, is one of 9 that started in 2020, is one of 15 in phase 2, and was the 82nd registered.

Retinitis Pigmentosa

278 studies on the registry are indexed under Retinitis Pigmentosa; 72 are open to participants now.

Browse Retinitis Pigmentosa studies →

Open to participants now

20 of the 119 studies in Retinitis Pigmentosa with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 49 Retinitis Pigmentosa studies recruiting now, 37 (76%) set no upper age limit and 7 (14%) stop at 75 or younger; 16 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 119 studies in Retinitis Pigmentosa with a site in United States, or all of them as a file.
02

Study summary

The primary objective of the study is to assess the safety of repeat injection of human retinal progenitor cells (jCell) in adult subjects with RP that have previously been treated with jCell.

Read the detailed description

This is a prospective, multi-center, single arm, Phase 2 study of human retinal progenitor cells (jCell) for the treatment of retinitis pigmentosa (RP). The study will include only subjects previously treated with jCell.

To assess reinjection of a previously treated eye, subjects who have previously been treated with jCell and desire a second treatment in the same eye will be enrolled. Subjects must have completed at least 12 months of follow up since the prior injection of jCell. Subjects who have had both eyes previously treated with jCell will only have one eye retreated; the eye to be retreated will preferably be the better seeing eye, but exceptions may be made by the study investigator, taking into consideration BCVA, prior response to treatment, and any other medical conditions that may indicate which eye is the best candidate for retreatment. Subjects will be followed for 12 months for safety and efficacy.

03

Conditions studied

  • Retinitis Pigmentosa

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing to give written , able to make the required study visits and follow study protocol instructions.
  2. Completed the 12 months of follow up in the subject's most recent jCell study and did not withdraw from the study for any reason.
  3. Adequate organ function:

    • blood counts (hematocrit, , WBC, and differential) within normal range, or if outside of normal range, not as judged by the investigator
    • liver function: [ALT] and aspartate transaminase [AST] ≤2 times the
    • total ≤1.5 times the upper limit of the normal range
    • renal function: serum creatinine ≤1.25 times the upper limit of the normal range
  4. A female patient of (not surgically sterilized and less than one year ) must have a negative pregnancy test (urine human chorionic gonadotropin) at entry (prior to injection) and must have used medically accepted for at least one month prior to treatment. Women of childbearing potential and men must be advised to use a medically accepted method of contraception for at least 12 months following treatment.

Exclusion criteria

Exclusion Criteria:

  1. , end-stage major organ disease (heart failure, significant arrhythmias, stroke or , diabetes, or state, major psychiatric disorder, epilepsy, thyroid disease, , renal failure, or any chronic systemic disease requiring continuous treatment with systemic , anticoagulants or immunosuppressive agents.
  2. History of eye disease other than RP that impairs visual function, including retinal vascular disease, elevated intraocular pressure/glaucoma, severe posterior uveitis, macular edema, media opacity precluding visual exam, amblyopia and/or longstanding constant strabismus, as well as patients who require other intravitreal therapies
  3. Allergy to penicillin or streptomycin.
  4. Adverse reaction to DMSO.
  5. Unable or unwilling to undergo pupil dilation, topical anesthesia or any protocol-required procedure.
  6. Women who are nursing or who are planning to nurse during the 12 months that would follow study treatment.
  7. Any circumstance that in the opinion of the investigator, would interfere with participation in, or compliance with the study protocol
  8. Treatment with corticosteroids (systemic, periocular or intravitreal) or any other non-approved, experimental, or neuroprotectant therapy (systemic, topical, intravitreal) in either eye within 90 days of planned second injection.
  9. Cataract surgery within three months prior to treatment or anticipated to need cataract surgery within a year of treatment
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Retreated subjects

    Subjects receiving human retinal progenitor cells (jCell) who have previously received jCell is a jCyte study.

    Biological: human retinal progenitor cells

Interventions

  • Biologicalhuman retinal progenitor cells

    single intravitreal injection of 6.0 million human retinal progenitor cells (hRPC)

    Also known as: jCell

06

What researchers measure

Primary outcomes

  1. Safety of Intravitreal Injection of hRPC

    Assessed by percentage of subjects with treatment emergent adverse events

    Time frame: 12 months

Secondary outcomes

  1. Best Corrected Visual Acuity (BCVA)

    Mean change in BCVA in study eye from baseline to month 12 as assessed by E-ETDRS. A letter score is used to compare change over time, with a higher number of letters representing better visual function, and a lower number of letters representing worse visual function. For example, 85 letters is equivalent to 20/20 visual acuity and 5 letters is equivalent to 20/800 visual acuity. A change value is derived for each subject by taking the letter score at 12 months and subtracting the letter score at baseline. A mean of all change values is then calculated.

    Time frame: 12 months

  2. Kinetic Visual Field Area

    Mean change in total kinetic visual field (KVF) area (degrees squared) of all islands of vision from baseline to 12 months. The Octopus 900 will be used for KVF testing using a specified target of V4e for subjects with a more severely impaired visual field (\<10,000deg2) and a target of III4e and I4e for better seeing subjects (\>10,000deg2). Target size is selected based on the Baseline visit. Whatever target size(s) is/are selected, the same size will be used throughout the study on that particular eye for that particular patient.

    Time frame: 12 months

  3. Contrast Sensitivity (Peak)

    Contrast sensitivity (CS) measures the ability of a subject to distinguish between finer and finer increments of light versus dark (contrast), as measured with a vertical striped pattern that varies in stripe width (cycles per degree or CPD); CS thresholds are created by taking the mean of multiple trials at each size of the target (i.e., at various CPDs). A CS curve is created by using the threshold of CS means at each target size, with the highest or most sensitive value (regardless of the CPD) representing the peak of the curve (i.e., peak contrast sensitivity). The unit of measure is therefore the peak contrast sensitivity regardless of the target size (i.e., CPD) being used to perform the measurement. The higher the value, the better the ability to detect contrast. The data shown here represent the mean change from Baseline to 12 months in the subjects' peak of the CS curve.

    Time frame: 12 months

  4. Low Luminance Mobility Test (LLMT)

    The LLMT identifies the performance of patients as they walk along an indoor pathway of arrows and obstacles at varying lighting levels. The Critical Illumination Level (CIL) is the light level below which the patient has a markedly slower pace and more errors than all light levels above (brighter than) that point. The LLMT uses light levels that go from very dim (0.12 lux) to a bright indoor room (500 lux), with evenly spaced increments that increase light by doubling the brightness of the room from the prior level. These evenly spaced light levels have been converted to a scale score to enable easier calculation of change scores. The dimmest light level of 0 lux (completely dark room) corresponds to a scale score of 13, whereas the brightest light level of 500 lux corresponds to a scale score of 0. A positive scale score change from baseline to 12 months represents improvement in low light vision, whereas a negative scale score change represents a decline in low light vision.

    Time frame: 12 months

07

Results

Posted Sep 26, 2023

Participant flow

Participant flow — Overall Study
MilestoneRetreated Subjects
Started30
Completed23
Not completed7

Outcome measures

PrimarySafety of Intravitreal Injection of hRPC

Assessed by percentage of subjects with treatment emergent adverse events

Time frame:
12 months
Reported as:
Count of participants · Participants
Safety of Intravitreal Injection of hRPC
ParticipantsRetreated Subjects
Subjects with any TEAEs15
Subjects with any TEAEs related/possibly related to study drug6
Subjects with any serious TEAEs6
Subjects with any serious TEAEs related/possibly related to study drug2
Subjects with any severe TEAEs related/possibly related to study drug1
SecondaryBest Corrected Visual Acuity (BCVA)

Mean change in BCVA in study eye from baseline to month 12 as assessed by E-ETDRS. A letter score is used to compare change over time, with a higher number of letters representing better visual function, and a lower number of letters representing worse visual function. For example, 85 letters is equivalent to 20/20 visual acuity and 5 letters is equivalent to 20/800 visual acuity. A change value is derived for each subject by taking the letter score at 12 months and subtracting the letter score at baseline. A mean of all change values is then calculated.

Time frame:
12 months
Reported as:
Mean · letters correct
Best Corrected Visual Acuity (BCVA)
letters correctRetreated Subjects
Best Corrected Visual Acuity (BCVA)-2.340 ± 5.8963
SecondaryKinetic Visual Field Area

Mean change in total kinetic visual field (KVF) area (degrees squared) of all islands of vision from baseline to 12 months. The Octopus 900 will be used for KVF testing using a specified target of V4e for subjects with a more severely impaired visual field (\<10,000deg2) and a target of III4e and I4e for better seeing subjects (\>10,000deg2). Target size is selected based on the Baseline visit. Whatever target size(s) is/are selected, the same size will be used throughout the study on that particular eye for that particular patient.

Time frame:
12 months
Reported as:
Mean · degrees squared
Kinetic Visual Field Area
degrees squaredRetreated Subjects
Kinetic Visual Field Area-493.96 ± 1268.067
SecondaryContrast Sensitivity (Peak)

Contrast sensitivity (CS) measures the ability of a subject to distinguish between finer and finer increments of light versus dark (contrast), as measured with a vertical striped pattern that varies in stripe width (cycles per degree or CPD); CS thresholds are created by taking the mean of multiple trials at each size of the target (i.e., at various CPDs). A CS curve is created by using the threshold of CS means at each target size, with the highest or most sensitive value (regardless of the CPD) representing the peak of the curve (i.e., peak contrast sensitivity). The unit of measure is therefore the peak contrast sensitivity regardless of the target size (i.e., CPD) being used to perform the measurement. The higher the value, the better the ability to detect contrast. The data shown here represent the mean change from Baseline to 12 months in the subjects' peak of the CS curve.

Time frame:
12 months
Reported as:
Mean · Arbitrary Units (AU)
Contrast Sensitivity (Peak)
Arbitrary Units (AU)Retreated Subjects
Contrast Sensitivity (Peak)-0.57 ± 6.690
SecondaryLow Luminance Mobility Test (LLMT)

The LLMT identifies the performance of patients as they walk along an indoor pathway of arrows and obstacles at varying lighting levels. The Critical Illumination Level (CIL) is the light level below which the patient has a markedly slower pace and more errors than all light levels above (brighter than) that point. The LLMT uses light levels that go from very dim (0.12 lux) to a bright indoor room (500 lux), with evenly spaced increments that increase light by doubling the brightness of the room from the prior level. These evenly spaced light levels have been converted to a scale score to enable easier calculation of change scores. The dimmest light level of 0 lux (completely dark room) corresponds to a scale score of 13, whereas the brightest light level of 500 lux corresponds to a scale score of 0. A positive scale score change from baseline to 12 months represents improvement in low light vision, whereas a negative scale score change represents a decline in low light vision.

Time frame:
12 months
Reported as:
Mean · scores on a scale
Low Luminance Mobility Test (LLMT)
scores on a scaleRetreated Subjects
Low Luminance Mobility Test (LLMT)-0.1 ± 1.96

Adverse events

Collected over 12 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Retreated Subjects (All Ocular AEs Were Reported in Study Eyes)2/30 (6.7%)6/30 (20%)6/30 (20%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventRetreated Subjects (All Ocular AEs Were Reported in Study Eyes)
Tractional retinal detachmentEye disorders1/30
Vitreoretinal traction syndromeEye disorders1/30
COVID-19Infections and infestations1/30
COVID-19 pneumoniaInfections and infestations1/30
PneumoniaInfections and infestations1/30
Acute left ventricular failureCardiac disorders1/30
Vertigo positionalEar and labyrinth disorders1/30
Non-small cell lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/30
Cerebrovascular accidentNervous system disorders1/30
HallucinationPsychiatric disorders1/30
Most frequent other events
Most frequent other events
EventRetreated Subjects (All Ocular AEs Were Reported in Study Eyes)
Conjunctival haemorrhageEye disorders6/30

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Retreated Subjects
Mean51.6 ± 13.93
Sex: Female, Male
Sex: Female, Male(Participants)Retreated Subjects
Female13
Male17
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Retreated Subjects
Hispanic or Latino5
Not Hispanic or Latino25
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Retreated Subjects
American Indian or Alaska Native0
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American1
White26
More than one race0
Unknown or Not Reported0
Height
Height(cm)Retreated Subjects
Mean170.14 ± 9.856
Weight
Weight(kg)Retreated Subjects
Mean84.00 ± 24.387
Study eye
Study eye(Participants)Retreated Subjects
Right (OD)14
Left (OS)16
08

Study locations

3 sites
  • Gavin Herbert Eye Inst, Univ Cal Irvine
    Irvine, California 92697, United States
  • Retina-Vitreous Associates Medical Group
    Los Angeles, California 90074, United States
  • Ophthalmic Consultants of Boston
    Boston, Massachusetts 02114, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in Mar 2022, 15 months.

Results were first posted in Sep 2023, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2020
First posted
Oct 27, 2020
StartActual
Dec 1, 2020
Primary completionActual
Mar 22, 2022
CompletionActual
Mar 22, 2022
Results first posted
Sep 26, 2023
Last update
Jul 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04604899
Lead sponsor
jCyte, Inc
Collaborators
California Institute for Regenerative Medicine (CIRM)
Responsible party
Sponsor
First posted
Oct 27, 2020
Start date
Dec 1, 2020
Primary completion
Mar 22, 2022
Completion
Mar 22, 2022
Results posted
Sep 26, 2023
Last update
Jul 16, 2024

Study contacts

Mitul Mehta, MD
principal investigator · University of California, Irvine/Gavin Herbert Eye Institute
David Liao, MD
principal investigator · Retina-Vitreous Associates Medical Group, Los Angeles CA
Anthony Jospeh, MD
principal investigator · Ophthalmic Consultants of Boston

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion